Aurinia Pharmaceuticals CEO and leadership

Mr. Stephen Zaruby W. is a President and Chief Executive Officer at AURINIA PHARMACEUTICALS INC and is based in United States.

Neil is responsible for managing, developing, guiding and coordinating Aurinia’s clinical development group and its activities. He is also Aurinia’s senior medical spokesperson to investigators, scientific advisors and investors. Neil is an experienced pharmaceutical physician with 15 years of clinical development and medical affairs experience in both big pharma and biotech. He is a recognised expert in rare-disease drug development and is widely published in this field. Neil joins Aurinia from Vifor Pharma, formerly Aspreva Pharmaceuticals (NASDAQ:ASPV) where he held the position of Vice President, Research and Development being the lead clinician in the development of CellCept® in rare diseases. Neil led the CellCept Clinical Development teams of over 50 people that saw the completion, reporting and publication of studies in pemphigus vulgaris, myasthenia gravis, both industry firsts, and the successful landmark lupus nephritis study called the Aspreva Lupus Management Study (ALMS). He was responsible for all clinical development activities from Phases 1 to 3, as well as participating in the formulation of R&D strategy, portfolio management, and due diligence efforts. Prior to Vifor & Aspreva, Neil held a variety of positions at Roche in both Global Clinical Development and Medical Affairs in transplantation, virology and auto-immune diseases. While at Roche, Neil led a diverse team in the development and implementation of post-marketing studies with a budget exceeding $15 million for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises. Neil qualified in medicine in 1991 receiving his MB BS (MD) at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing specialist training in anesthesia and intensive care. His research interests included sepsis and chronic pain.

Richard Glickman has served as Chairman of ESSA’s board of directors since October 2010, and is responsible for the management of the board of directors to ensure ESSA has appropriate objectives, an effective strategy and is operating in accordance with a high standard of corporate governance. Richard was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. Prior to establishing Aspreva, Richard was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Richard currently serves on the board of directors of Cardiome, Vida Pharmaceuticals and Engene Inc., and is Chairman of the board of directors of Aurinia Pharmaceuticals Inc. In addition, Richard has served on many other biotechnology boards of directors. Richard received the 2004 Ernst & Young Entrepreneur of the Year Award for the Pacific Region Life Sciences Group, both Canada's and British Columbia's Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.

Senior Level Executive with extensive hands-on experience in management, business leadership and working with the Board of Directors, Audit Committee, banks, accountants and attorneys. CPA with an established track record of success in growing enterprise value. Consistently employ an energized can-do management style utilizing financial analysis skills, organizational abilities, vision and tenacity. Blend motivation, leadership, creativity and analytical abilities to develop and implement innovative ideas that produce bottom-line results.

Stephen P Robertson is a Secretary and Director at Carousel Theatre Society, Exec VP/Chief Compliance Ofcr/Secy/Gen CSL at AURINIA PHARMACEUTICALS INC, and Adjunct Professor at University of British Columbia and is based in Vancouver, British Columbia, Canada. He has worked as Chair at Securities Law Section of the BC Branch of the Canadian Bar Association, Secretary at AURINIA PHARMACEUTICALS INC, and Secretary/Treasurer at Securities Law Section of the BC Branch of the Canadian Bar Association. Stephen attended Burnaby North Secondary, Simon Fraser University between 2000 and 2004, and University of Manitoba between 2004 and 2007.

Neil is responsible for managing, developing, guiding and coordinating Aurinia’s clinical development group and its activities. He is also Aurinia’s senior medical spokesperson to investigators, scientific advisors and investors. Neil is an experienced pharmaceutical physician with 15 years of clinical development and medical affairs experience in both big pharma and biotech. He is a recognised expert in rare-disease drug development and is widely published in this field. Neil joins Aurinia from Vifor Pharma, formerly Aspreva Pharmaceuticals (NASDAQ:ASPV) where he held the position of Vice President, Research and Development being the lead clinician in the development of CellCept® in rare diseases. Neil led the CellCept Clinical Development teams of over 50 people that saw the completion, reporting and publication of studies in pemphigus vulgaris, myasthenia gravis, both industry firsts, and the successful landmark lupus nephritis study called the Aspreva Lupus Management Study (ALMS). He was responsible for all clinical development activities from Phases 1 to 3, as well as participating in the formulation of R&D strategy, portfolio management, and due diligence efforts. Prior to Vifor & Aspreva, Neil held a variety of positions at Roche in both Global Clinical Development and Medical Affairs in transplantation, virology and auto-immune diseases. While at Roche, Neil led a diverse team in the development and implementation of post-marketing studies with a budget exceeding $15 million for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises. Neil qualified in medicine in 1991 receiving his MB BS (MD) at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing specialist training in anesthesia and intensive care. His research interests included sepsis and chronic pain.

Richard Glickman has served as Chairman of ESSA’s board of directors since October 2010, and is responsible for the management of the board of directors to ensure ESSA has appropriate objectives, an effective strategy and is operating in accordance with a high standard of corporate governance. Richard was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. Prior to establishing Aspreva, Richard was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Richard currently serves on the board of directors of Cardiome, Vida Pharmaceuticals and Engene Inc., and is Chairman of the board of directors of Aurinia Pharmaceuticals Inc. In addition, Richard has served on many other biotechnology boards of directors. Richard received the 2004 Ernst & Young Entrepreneur of the Year Award for the Pacific Region Life Sciences Group, both Canada's and British Columbia's Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.

Richard Glickman has served as Chairman of ESSA’s board of directors since October 2010, and is responsible for the management of the board of directors to ensure ESSA has appropriate objectives, an effective strategy and is operating in accordance with a high standard of corporate governance. Richard was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Inc. Prior to establishing Aspreva, Richard was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Richard currently serves on the board of directors of Cardiome, Vida Pharmaceuticals and Engene Inc., and is Chairman of the board of directors of Aurinia Pharmaceuticals Inc. In addition, Richard has served on many other biotechnology boards of directors. Richard received the 2004 Ernst & Young Entrepreneur of the Year Award for the Pacific Region Life Sciences Group, both Canada's and British Columbia's Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.